← Back to Screener
Veracyte, Inc. (VCYT)
Price$48.18
Value ScoreD
Growth ScoreA
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-2.49%
Price vs S&P 500 (4W)35.07%
VGM Score60.16
Market Capitalization$3.70B
P/E Ratio (Annual)55.73x
All Metrics
P/CF (Annual)27.13x
Book Value / Share (Quarterly)$16.85
P/TBV (Annual)2.73x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)20.37%
Cash Flow / Share (Quarterly)$1.95
Price vs S&P 500 (YTD)-0.86%
Gross Margin (TTM)70.92%
Net Profit Margin (TTM)16.25%
EPS (TTM)$1.08
10-Day Avg Trading Volume1.13M
EPS Excl Extra (TTM)$1.08
Revenue Growth (5Y)34.50%
EPS (Annual)$0.82
ROI (Annual)5.07%
Gross Margin (Annual)70.10%
Net Profit Margin (5Y Avg)-9.83%
Cash / Share (Quarterly)$5.50
P/E Basic Excl Extra (TTM)42.01x
Revenue Growth QoQ (YoY)21.49%
P/E Normalized (Annual)55.73x
ROA (Last FY)4.72%
Revenue Growth TTM (YoY)16.91%
EBITD / Share (TTM)$1.04
ROE (5Y Avg)-2.06%
Operating Margin (TTM)14.31%
Cash Flow / Share (Annual)$1.60
P/B Ratio2.75x
P/B Ratio (Quarterly)1.91x
Net Income / Employee (Annual)$87,900
EV / Revenue (TTM)6.34x
Net Interest Coverage (TTM)-67.00x
ROA (TTM)6.34%
EPS Growth QoQ (YoY)301.14%
EV / EBITDA (TTM)40.94x
EPS Incl Extra (Annual)$0.82
Current Ratio (Annual)8.15x
Quick Ratio (Quarterly)8.72x
3-Month Avg Trading Volume0.96M
52-Week Price Return71.88%
EV / Free Cash Flow (Annual)27.12x
P/E Incl Extra (TTM)42.01x
Revenue / Employee (TTM)$717,500
Tangible BV / Share (Quarterly)$15.77
P/S Ratio (Annual)7.15x
Asset Turnover (Annual)0.37x
52-Week High$50.71
Operating Margin (5Y Avg)-12.03%
EPS Excl Extra (Annual)$0.82
CapEx CAGR (5Y)27.79%
Tangible BV CAGR (5Y)27.56%
26-Week Price Return13.44%
Quick Ratio (Annual)7.63x
13-Week Price Return19.59%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.31x
Enterprise Value$3.43B
Revenue / Share Growth (5Y)23.78%
Asset Turnover (TTM)0.39x
Book Value / Share Growth (5Y)17.92%
Revenue / Employee (Annual)$685,000
Inventory Turnover (Annual)7.31x
Pretax Margin (Annual)13.19%
Cash / Share (Annual)$5.20
3-Month Return Std Dev72.52%
Gross Margin (5Y Avg)67.52%
Net Income / Employee (TTM)$116,600
ROE (Last FY)5.07%
Net Interest Coverage (Annual)-75.72x
EPS Basic Excl Extra (Annual)$0.82
P/FCF (TTM)23.80x
Receivables Turnover (TTM)10.43x
EV / Free Cash Flow (TTM)22.11x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$1.08
Receivables Turnover (Annual)11.34x
ROI (TTM)6.86%
P/S Ratio (TTM)6.83x
Pretax Margin (5Y Avg)-10.34%
Revenue / Share (Annual)$6.42
Tangible BV / Share (Annual)$15.38
Forward P/E43.74x
Price vs S&P 500 (52W)43.68%
P/E Ratio (TTM)42.01x
EPS Growth TTM (YoY)158.49%
Year-to-Date Return10.07%
5-Day Price Return2.91%
EPS Normalized (Annual)$0.82
ROA (5Y Avg)-1.92%
Net Profit Margin (Annual)12.83%
Month-to-Date Return40.77%
Cash Flow / Share (TTM)$-0.31
EBITD / Share (Annual)$0.82
Operating Margin (Annual)11.17%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)22.25x
ROI (5Y Avg)-2.06%
P/E Excl Extra (TTM)42.01x
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$1.08
P/TBV (Quarterly)2.04x
P/B Ratio (Annual)2.54x
Inventory Turnover (TTM)6.90x
Pretax Margin (TTM)16.75%
Book Value / Share (Annual)$16.50
Price vs S&P 500 (13W)9.84%
Beta2.01x
P/FCF (Annual)29.20x
Revenue / Share (TTM)$6.66
ROE (TTM)6.86%
52-Week Low$22.61
vGradeD
gGradeA
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 260.35est. 0.15
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.11
4.11
4.21
4.22
Industry Peers — Health Services(28)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VCYTVeracyte, Inc. | D | A | B | $48.18 |
| NTRANatera, Inc. Common Stock | F | A | B | $218.81 |
| DGXQuest Diagnostics Inc. | C | D | C | $192.20 |
| LHLabcorp Holdings Inc. | C | D | C | $256.87 |
| EXASExact Sciences Corp | F | B | B | $0.00 |
| GHGuardant Health, Inc. Common Stock | F | A | A | $129.14 |
| CELCCelcuity Inc. Common Stock | — | — | B | $122.96 |
| CAICaris Life Sciences, Inc. Common Stock | F | F | C | $16.45 |
| RDNTRadNet, Inc. Common Stock | D | C | D | $52.89 |
| GRALGRAIL, Inc. Common Stock | D | A | B | $64.40 |
| FTREFortrea Holdings Inc. Common Stock | B | F | A | $15.76 |
About
Veracyte is a genomic diagnostics company providing molecular tests to help clinicians diagnose and treat cancer across multiple tumor types. Its portfolio includes Decipher tests for prostate and bladder cancer, Afirma for thyroid cancer, and Prosigna for breast cancer. These precision diagnostics enable informed clinical decision-making and improve patient outcomes at critical treatment junctures.